Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

TIBSOVO (ivosidenib) for Relapsed or Refractory AML

Drug Name

TIBSOVO® (ivosidenib)

Developer

Agios Pharmaceuticals

Therapy Class

Small molecule inhibitor

Product Description

Isocitrate dehydrogenase-1 (IDH1) enzyme inhibitor

Current Indication

Relapsed or refractory acute myeloid leukaemia

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top